Tipsheet
What matters at India’s listed companies
Earnings · Consumer Goods · Micro cap

JHS Svendgaard narrows annual losses as revenue climbs to ₹10,169.47 lakhs

The oral care manufacturer cut its annual net loss to ₹191.73 lakhs for FY26, though a fourth-quarter loss of ₹356.56 lakhs keeps the company in the red.

1 earlier story on JHS Svendgaard Laboratories Ltd.
Mkt cap₹79 cr
ROE0.00%
Debt / eq.0.03
₹191.73 lakhs Annual net loss for FY26, down from ₹1,973.84 lakhs in FY25.

What's new

  • Annual revenue grew to ₹10,169.47 lakhs from ₹9,199.73 lakhs.
  • Q4 standalone net loss narrowed to ₹356.56 lakhs from ₹695.67 lakhs a year ago.
  • Auditor V.K. Khosla & Co. flagged capital advances of ₹2,862.52 lakhs and ₹1,328.30 lakhs.

Why this matters

While the narrowing of losses is a positive trend, the company remains unprofitable. The auditor's focus on capital advances for projects in Himachal Pradesh and Jammu & Kashmir is a critical watch item for cash flow visibility.

What we're watching

  • Conversion of capital advances into operational facilities.
  • Management's ability to turn a quarterly profit in FY27.
  • Debt servicing capacity given the company's net debt position.

The full read

JHS Svendgaard Laboratories trimmed its annual net loss to ₹191.73 lakhs for the year ended March 31, 2026, a sharp improvement from the ₹1,973.84 lakhs loss reported in the prior year. Revenue grew to ₹10,169.47 lakhs from ₹9,199.73 lakhs. Despite the annual progress, the company remains loss-making, posting a ₹356.56 lakhs loss in the fourth quarter alone. The auditor, V.K. Khosla & Co., issued an unmodified opinion but flagged capital advances of ₹2,862.52 lakhs for facilities in Himachal Pradesh and ₹1,328.30 lakhs for pre-emption rights in Jammu & Kashmir. Management maintains these are recoverable. With total equity at ₹17,507.76 lakhs and fresh borrowings taken during the year, the company's ability to convert these large advances into productive assets is the next test.

Questions answered

How did the annual financial performance change year-over-year?
JHS Svendgaard reduced its net loss to ₹191.73 lakhs for the year ended March 31, 2026, compared to a loss of ₹1,973.84 lakhs in the previous fiscal year.
What did the auditor highlight in the financial statements?
The auditor issued an unmodified opinion but drew attention to ₹2,862.52 lakhs in advances for Himachal Pradesh facilities and ₹1,328.30 lakhs for pre-emption rights in Jammu & Kashmir.
Is the company currently profitable?
No. The company reported a standalone net loss of ₹356.56 lakhs for the fourth quarter of FY26.
What is the company's current equity position?
Total equity stood at ₹17,507.76 lakhs at the end of the fiscal year.
Mentioned: JHS Svendgaard Laboratories · V.K. Khosla & Co.
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on JHS →
  1. 26 May 2026 · 7:08 PM IST JHS Svendgaard narrows annual losses as revenue climbs to ₹10,169.47 lakhs
  2. today JHS Svendgaard narrows annual losses to ₹191.73 lakhs